Navigation Links
OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
Date:4/28/2009

a clinical trial to support a regulatory submission. This agreement can be in writing and cannot be changed after the clinical trial begins except: (i) with written agreement of the company and the FDA; or (ii) if the director of the FDA reviewing division determines that "a substantial scientific issue essential to determining the safety or effectiveness of the drug" was identified after testing began.

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed enrollment in a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at www.oncogenex.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning the potential survival benefit of OGX-011, anticipated clinical development activities, timing of these activities, the ability of future trials to demonstrate clinical benefit and the potential for regulatory approvals. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties a
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade hypothermic storage and cryopreservation freeze ... and tissues  ("BioLife" or the "Company"), today announced that it ... 4, 2015 (the "Annual Meeting"). Because the expected ...
(Date:12/24/2014)... December 23, 2014 GMO corn cases filed ... are in the process of being consolidated in a Kansas ... Re: Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 ... , Management of the Syngenta GMO corn multidistrict litigation (MDL) ...
(Date:12/24/2014)... SoundConnect’s 2015 next generation ... communication technology, provide continued education and inform users ... demonstrates online communication features and benefits; empowering users ... innovative and powerful tools. , According to SoundConnect’s ...
(Date:12/24/2014)... Island, New York (PRWEB) December 23, 2014 ... and the Long Island Affiliate of ITRA Global, the national ... slow but steady recovery. This is evidenced by the ... the strong stock market. Low energy costs have held ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... Turner Fellow at Stony Brook University (SBU), will give ... in Philadelphia on controlling the size of nanoclusters, research ... Department of Energy,s Brookhaven National Laboratory. Built by Brookhaven ... make nanoclusters of 10 to 100 atoms with atomic ...
... Technology (NIST) and the Joint Quantum Institute (JQI), a ... have reported a new way to fine-tune the light ... of lasers. Their technique, published in Physical Review ... source of pairs of entangled photons, a property with ...
... New Contracts Valued at $115.5 Million Signed in Fourth ... ARAY ), a global leader in the field ... and fiscal year,ended June 28, 2008., For the ... $50.9 million, a 16 percent increase over fourth quarter ...
Cached Biology Technology:Light touch: Controlling the behavior of quantum dots 2Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 2Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 3Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 4Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 5Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 6Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 7Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 8Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 9
(Date:1/22/2015)... Technology Showcase, Hall E -   EyeLock Inc. , ... it will showcase its EyeLock ID technology integrated in a ... Energy,s Oak Ridge National Laboratory (ORNL) at the ... identity authentication technology is being used to validate the driver ...
(Date:1/22/2015)...  Analyst Report Issued by Small Cap IR. In 2011, Nilson ... transactions at merchants on the leading payment cards rose to ... debit, and prepaid cards reached 6.54 billion.  Eight million credit ... usage in 2012, and credit and debit card fraud resulted ...
(Date:12/24/2014)... its launch in December 2014, the 1U™ app ... trying to remember their usernames and passwords through replacing the ... To assist people who have struggled to remember usernames and ... and focuses on redefining identity, announced today that it is ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... of the International Society for Sexually Transmitted Disease Research ... City, Canada. The world,s foremost conference in the ... from every continent to discuss the most recent developments ... emerging threats in bacterial STDs; major intervention programs for ...
... University of Georgia researcher has invented a new ... clothing, face masks, paper towelsand yes, even diapers, ... germ-free. The simple and inexpensive anti-microbial technology ... can be applied during the manufacturing process or ...
... are developing new technologies that combine a laser ... particles such as bacteria, viruses and DNA for ... to food safety. The technologies could bring ... or miniature instruments that perform measurements normally requiring ...
Cached Biology News:New UGA technology makes textiles permanently germ-free; targets health care-associated infections 2New UGA technology makes textiles permanently germ-free; targets health care-associated infections 3Laser, electric fields combined for new 'lab-on-chip' technologies 2Laser, electric fields combined for new 'lab-on-chip' technologies 3
In Western blotting antibodies recognize 94 K protein band, which corresponds to S-layer protein...
... Antibiotic isolated fromStreptomyces griseolusthat inhibits ... transferase activity in eukaryote ribosomes. Reported ... of cells including promyelocytic leukemia cells, ... adenocarcinoma cells. Initiates intracellular signals and ...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
... and, until recently, no readily available affinity chromatography ... methods for IgM purification generally are multi-step, tedious ... all of the major impurities present in IgM ... developed an easy-to-use affinity matrix and buffer system ...
Biology Products: